US FDA declines to approve Camurus' rare hormone disorder drug
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...
FiercePharma6h
FDA stymies Camurus' hormonal disorder drug due to 3rd-party manufacturing issues
The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...
BioSpace7h
FDA Rejects Camurus’ Rare Hormonal Disorder Treatment Due to Manufacturing Problems
The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...
MedPage Today1h
Acromegaly Injectable Rejected; Nobel Prize Winner Dies; Obesity Doubles in Kids
In a phase III trial of adults with type 2 diabetes with heart disease and/or chronic kidney disease, oral semaglutide ...
Monthly Prescribing Reference2h
Manufacturing Issue Delays Decision on Acromegaly Therapy
CAM2029 is a novel depot formulation of octreotide, a somatostatin analogue, administered subcutaneously once monthly.
ENDPOINTS NEWS9h
FDA hits Ca­mu­rus with CRL for acromegaly ther­a­py over man­u­fac­tur­ing is­sues
The FDA handed a CRL to the Swedish biotech Camurus for its hormone disorder therapy over “facility-related deficiencies” at ...
BioSpace8d
FDA Action Alert: Amgen, Camurus, Iterum and Lexicon
The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...
devdiscourse7h
Global Health Dynamics: From Bird Flu to Breakthroughs
In a summary of current health news: the CDC investigates bird flu in Washington, David Joyner becomes CVS CEO, China tackles ...
Indivior's opioid treatment sales slump prompts second profit warning
British drugmaker Indivior on Thursday cut its 2024 net revenue forecast for the second time in three months, citing lower ...
Jefferies Remains a Buy on Camurus AB (CAMRF)
Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) today and set a price target of ...
Jefferies Sticks to Its Buy Rating for Camurus AB (CAMRF)
Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) on October 11 and set a price target of ...
Seeking Alpha2mon
CAMRF Camurus AB (publ)
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company ...